News
Early adopters share first-hand experience with Cryoimmunostaining™ technology
Halle (Saale), November 2025 – After breaking new ground last year by featuring Cryoimmunostaining™ in the official scientific programme for the first time, the 2025 Seminar on Clinical Cytology in Pulmonology in Halle (Saale), Germany once again placed...
New data confirms routine utility of Cryoimmunostaining™ for effusion and FNA samples
Ljubljana, October 2025 – New clinical data on multiplex Cryoimmunostaining™ took centre stage at an international science conference in Ljubljana, Slovenia, where digital cytology pioneer X-ZELL featured prominently as part of the RadEx IOR Boost project, an...
X-ZELL launches new Cryophore range of expert vetted antibody panels
Florence , May 2025 – X-ZELL is proud to announce the new Cryophore™ range of standardized multiplex antibody panels, developed in close collaboration with leading experts and WHO guideline authors from Europe and the United States. X-ZELL Founder & CEO, Dr...
German cytology conference marks historic milestone for multiplex immunostaining
Halle, November 2024 — A forward-looking panel discussion on the future of multiplex immunostaining took centre stage at the 2024 Seminar on Clinical Cytology in Pulmonology in Halle, Germany, marking a pivotal moment for Cryoimmunostaining™ and its role in routine...
X-ZELL outperforms traditional immunostaining in German landmark study
Leipzig, July 2024 – New research from Germany has shown that X-ZELL technology could dramatically reduce the number of inconclusive cancer diagnoses from minimally invasive sample material. During a lecture given at the 45th European Congress of Cytology (ECC) in...
X-ZELL launches Global Technology Trial
Leipzig, June 2024 – To celebrate the 45th anniversary of the European Congress of Cytology (ECC) in Leipzig, Germany, X-ZELL has announced the launch of an international Technology Trial program. X-ZELL Founder & CEO, Dr Sebastian Bhakdi, unveiled the new...
X-ZELL technology now US FDA-listed and IVDR-compliant
Singapore, March 2024 – X-ZELL is proud to announce that the company’s ground-breaking Next-Generation Cytology (NGC) technology is now officially available for routine use in Europe and the US. X-ZELL NGC is a platform technology combining next-generation...
X-ZELL Live Experience Tour wrapped
Singapore, November 2023 – X-ZELL’s first global conference tour has officially wrapped after the series’ final instalment at the Annual Scientific Meeting of the American Society of Cytopathology (ASC) in Austin, Texas, USA. Aimed at promoting X-ZELL’s Next...
X-ZELL enabling same-day diagnoses at German routine laboratory
Budapest, October 2023 – New research has shown that X-ZELL Cryoimmunostaining™ is able to facilitate same-day cancer diagnoses from minimally invasive samples in routine clinical practice PD Dr. med. Achim Battmann, MD, PhD, chief pathologist at MVZ Frankfurt, a...
X-ZELL technology used for novel T cell therapy
Singapore, September 2023 – A research team at Duke-NUS Medical School in Singapore has developed a T cell therapy that could play an important role in treating cancer recurrences after liver transplants. The new treatment, called IDRA HBV-TCR*, is able to target and...
© 2024 X-ZELL Biotech Pte. Ltd.
Find Us